初治慢性乙型肝炎患者接受替诺福韦艾拉酚胺96周治疗期间的脂质安全性

Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients.

作者信息

Zhao Wenjuan, Liu Yi, Zhang Mengdi, Cui Zixin, Qu Zhan, Li Yiyang, Wan Meijuan, Wang Wen, Chen Yunru, Shi Lei, Li Jianzhou, Ye Feng

机构信息

Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.

Department of Nutrition, Xian Jiaotong University, Xi'an, China.

出版信息

Front Med (Lausanne). 2024 Jun 4;11:1399665. doi: 10.3389/fmed.2024.1399665. eCollection 2024.

BACKGROUND

This study was aimed at investigating the dynamics of lipids and the effect of TAF on the lipid profile of patients including fatty liver disease in CHB patients.

METHODS

The data of TC, LDL-c, HDL-c, TG, and TC/HDL ratio were collected at baseline, 24 weeks, 48 weeks, 72 weeks, and 96 weeks. CHB patients with fatty liver at baseline were further analyzed in a subgroup.

RESULTS

A total of 137 CHB patients treated with TAF were enrolled in this study. During 96 weeks of TAF treatment, there was no significant change in TC, LDL-c, HDL-c, and TG level ( > 0.05). The TC/HDL-c ratio was increased with no significant change (+0.24, > 0.05). In CHB patients with fatty liver ( = 48), TC, LDL-c, and TC/HDL-c ratio increased gradually during TAF treatment, TG levels increased to 146.63 mg/dL at 48 weeks ( = 0.057) and then decreased, but there was still no significant change compared with the baseline level by 96 weeks ( > 0.05).

CONCLUSION

TAF treatment had a low effect on the lipid profile of CHB patients over the course of 96 weeks, and it was safe even in patients with fatty liver.

CLINICAL TRIAL REGISTRATION

[https://www.chictr.org.cn/showproj.html?proj=65123], identifier [ChiCTR2000041005].

背景

本研究旨在调查慢性乙型肝炎（CHB）患者脂质的动态变化以及替诺福韦艾拉酚胺（TAF）对包括脂肪肝疾病在内的患者脂质谱的影响。

方法

收集基线、24周、48周、72周和96周时的总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-c）、高密度脂蛋白胆固醇（HDL-c）、甘油三酯（TG）以及TC/HDL比值的数据。对基线时患有脂肪肝的CHB患者进行亚组进一步分析。

结果

本研究共纳入137例接受TAF治疗的CHB患者。在TAF治疗的96周期间，TC、LDL-c、HDL-c和TG水平无显著变化（P>0.05）。TC/HDL-c比值升高但无显著变化（+0.24，P>0.05）。在患有脂肪肝的CHB患者（n=48）中，TAF治疗期间TC、LDL-c和TC/HDL-c比值逐渐升高，TG水平在48周时升高至146.63mg/dL（P=0.057），随后下降，但到96周时与基线水平相比仍无显著变化（P>0.05）。